Oncomed Pharmaceuticals Inc., of San Francisco, reported Phase Ib data of demcizumab combined with gemcitabine and Abraxane (nab-paclitaxel, Celgene Corp.) in first-line Stage IV pancreatic cancer, showing it was generally well tolerated, with fatigue, hypertension, nausea and vomiting the most common drug-related toxicities.